Johnson & Johnson (JNJ)
Johnson & Johnson: You Need To Look At This Chart (Rating Upgrade)
JNJ's current dividend yield is around the highest level in at least 10 years. The market's concern over its current issues - which are all temporary in my view - is drastically overblown. The overreaction has created a severe mispricing for this sector leader with superb financial strength and stable growth outlook.
Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Johnson & Johnson (JNJ) Completes Acquisition of V-Wave Ltd for $600 Million
Johnson & Johnson (JNJ, Financial) has finalized the acquisition of V-Wave Ltd, a private medical device company. The pharmaceutical giant agreed to purchase V-Wave for an upfront payment of $600 million.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Should Investors Consider High Yield Dividend Stocks?
When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield.
What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week?
Monday, Johnson & Johnson JNJ said it discontinued the Phase 3 SunRISe-2 trial of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy for muscle-invasive urothelial carcinoma (MIBC) patients who are not receiving radical cystectomy.
Analysts Estimate Johnson & Johnson (JNJ) to Report a Decline in Earnings: What to Look Out for
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Johnson & Johnson (JNJ) Halts TAR-200 Bladder Cancer Trial, Future FDA Plans Remain
Johnson & Johnson (JNJ, Financial) has announced the termination of its phase 2 trial for the TAR-200 therapy aimed at treating patients with muscle-invasive bladder cancer (MIBC). The decision followed an interim analysis from the SunRISe-2 study, which indicated no advantage over existing chemo-radiation treatments.
J&J discontinues late-stage study for bladder cancer drug
Johnson & Johnson said on Monday it has discontinued a late-stage study testing its experimental drug to treat a type of bladder cancer as the drug did not show superior benefits compared to chemoradiation.
Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.
Johnson & Johnson Scraps Phase II Study on Antiviral for Dengue Virus
As part of the strategic re-prioritization, JNJ terminates the phase II field study on mosnodenvir for the prevention of the dengue virus.
Top 3 Risk-Averse Stocks to Add Stability to Your Portfolio
While some investors relish the thrill of high-growth ventures with the potential for significant returns, others prioritize capital preservation and seek out investments that offer security and stability. This approach, known as risk aversion, is a core concept for investors seeking to minimize portfolio volatility and protect their principal investment.
